閉尿症治療市場規模、佔有率和成長分析：按療法、病因、通路、最終用戶和地區分類－2026-2033年產業預測

2024 年全球閉尿症治療市場價值為 15.2 億美元，預計到 2025 年將成長至 16.1 億美元，到 2033 年將成長至 25.2 億美元，在預測期（2026-2033 年）內複合年成長率為 5.81%。

全球閉尿症治療市場涵蓋藥物、微創醫療設備以及旨在解決急性和慢性膀胱出口阻塞的外科手術。該市場的主要促進因素是老年男性、神經系統疾病患者和術後患者中閉尿症的高發生率，凸顯了對有效治療方法的迫切需求。治療進展正從常用的抗膽鹼能藥物轉向更先進的α阻斷劑和磷酸二酯酶-5抑制劑。攝護腺尿道提升術和暫時分流術等創新技術正在改變市場格局，而術後排尿功能障礙（尤其是根治性護腺切除術後）發生率的不斷上升，則推動了持續的研發投入。製藥公司與醫療設備新創公司之間的合作正在加速技術進步，改善患者預後，並為醫療保健生態系統中的製造商拓展商機。

全球閉尿症治療市場的成長要素

全球人口老化是閉尿症治療市場成長的主要促進因素。這是因為與老齡化相關的膀胱功能障礙導致該年齡層中閉尿症的發生率不斷上升。在以改善老年人生活品質為重點的醫療保健系統下，有效的管理策略尤其重要，從而推動了藥物和醫療設備解決方案的普及。臨床病例的持續成長正在推動市場擴張，並刺激對創新療法的投資。此外，看護者對早期症狀識別意識的提高，有助於及時將患者轉診至專科醫生，從而增加了對先進療法的需求。

全球閉尿症治療市場面臨的限制因素

創新閉尿症治療，尤其是涉及先進醫療設備和生物製藥的治療，高成本給醫療服務提供者和患者都帶來了沉重的經濟負擔。保險公司往往優先考慮成本效益高的替代方案，導致保險覆蓋範圍有限。因此，儘管新療法具有潛在優勢，醫療專業人員仍可能選擇價格較低廉的傳統療法。這種經濟挑戰限制了尖端解決方案的廣泛應用，並阻礙了價格敏感地區的市場成長。反過來，這又減緩了這些創新技術的應用和真實世界數據（REW）的積累，從而對支付方的信心產生負面影響，並阻礙了整體市場擴張。

全球閉尿症治療市場趨勢

全球閉尿症治療市場正經歷著向微創介入治療的顯著轉變，這種轉變旨在提高患者舒適度並縮短復原時間。可程式設計神經刺激植入和矽膠間歇導尿管等創新技術的應用，正在改變傳統的治療模式，在有效控制症狀的同時，最大限度地減少併發症。隨著醫療專業人員越來越傾向於這些先進的解決方案，製造商也加大研發投入，將智慧材料和無線連接技術融入產品中。這一趨勢表明，在以患者滿意度和生活品質為優先的微創療法需求的推動下，市場將持續成長。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球閉尿症治療市場規模：依治療方法分類

• α1阻斷劑（Tamsulosin）
• 5α-還原酶抑制劑
• 導管插入
• 手術介入（經尿道攝護腺切除術）

全球閉尿症治療市場規模：依病因分類

• 良性攝護腺增生（BPH）
• 神經源性
• 藥物誘發

全球閉尿症治療市場規模：按通路分類

• 零售藥房
• 醫院藥房

全球閉尿症治療市場規模：依最終用戶分類

• 泌尿系統診所
• 醫院

全球閉尿症治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Astellas Pharma（Flomax）
• GlaxoSmithKline（Avodart）
• Pfizer Inc.
• Boehringer Ingelheim
• Merck & Co.
• AbbVie Inc.
• Teva Pharmaceutical
• Mylan（Viatris）
• Sun Pharmaceutical
• Dr. Reddy's Laboratories
• Bayer AG
• Cipla Ltd.
• NovaBay Pharmaceuticals
• Medtronic plc（UroLift）
• NxStage Medical（Fresenius）
• Coloplast A/S
• CR Bard（Becton Dickinson）
• Rochester Medical
• Teleflex Inc.
• CR Bard Inc.

結論與建議

Global Urinary Retention Therapeutics Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.61 Billion in 2025 to USD 2.52 Billion by 2033, growing at a CAGR of 5.81% during the forecast period (2026-2033).

The global urinary retention therapeutics market includes pharmaceuticals, minimally invasive devices, and surgical interventions aimed at addressing both acute and chronic bladder outlet obstruction. This market is driven by the prevalence of urinary retention among older men, individuals with neurological disorders, and post-surgical patients, highlighting the pressing need for effective management options. The evolution of treatments has shifted from generic anticholinergics to advanced a-blockers and phosphodiesterase-5 inhibitors. Innovations such as prostatic urethral lifts and temporary shunts are reshaping the landscape, while the increasing incidence of post-operative urinary dysfunction, particularly following radical prostatectomy, propels ongoing research and development. Collaborations between pharmaceutical companies and medical-device startups are fostering advancements, leading to improved patient outcomes and enhanced revenue opportunities for manufacturers within the healthcare ecosystem.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Urinary Retention Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Urinary Retention Therapeutics Market Segments Analysis

Global urinary retention therapeutics market is segmented by treatment type, cause, distribution, end-user and region. Based on treatment type, the market is segmented into Alpha-1 Blockers (Tamsulosin), 5-Alpha Reductase Inhibitors, Catheterization and Surgical Intervention (TURP). Based on cause, the market is segmented into Benign Prostatic Hyperplasia (BPH), Neurogenic and Drug-Induced. Based on distribution, the market is segmented into Retail Pharmacies and Hospital Pharmacies. Based on end-user, the market is segmented into Urology Clinics and Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Urinary Retention Therapeutics Market

The increasing global demographic shift toward older adults significantly contributes to the growth of the urinary retention therapeutics market, as age-related bladder dysfunction leads to a higher incidence of urinary retention among this population. With healthcare systems dedicated to enhancing the quality of life for seniors, there is a notable emphasis on effective management strategies, resulting in a greater uptake of both pharmaceutical and device-based solutions. This ongoing rise in clinical cases fosters market expansion and prompts investment in innovative treatment methods. Additionally, improved awareness among caregivers regarding early symptom identification encourages prompt referrals, thereby elevating the demand for advanced therapeutic options.

Restraints in the Global Urinary Retention Therapeutics Market

The high cost associated with innovative urinary retention therapeutics, particularly advanced devices and biologics, creates a significant financial strain on both healthcare providers and patients. This often leads to limited reimbursement options, as insurers tend to favor cost-effective alternatives. Consequently, healthcare professionals may opt for older, more affordable treatments, despite the potential benefits of newer therapies. This economic challenge restricts the widespread adoption of cutting-edge solutions, impeding market growth in regions sensitive to pricing. As a result, the slower integration of these innovations and the generation of real-world evidence negatively impact payer confidence and hinder the overall expansion of the market.

Market Trends of the Global Urinary Retention Therapeutics Market

The Global Urinary Retention Therapeutics market is witnessing a significant shift towards minimally invasive interventions that enhance patient comfort and reduce recovery times. The adoption of innovative technologies, including programmable neurostimulation implants and silicone-based intermittent catheters, is transforming traditional treatment paradigms by offering effective symptom management with minimal complications. As healthcare professionals increasingly favor these advanced solutions, manufacturers are investing in research and development to incorporate smart materials and wireless connectivity into their products. This trend indicates a sustained momentum in the market, driven by the demand for less invasive therapies that prioritize patient satisfaction and quality of life.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Urinary Retention Therapeutics Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Alpha-1 Blockers (Tamsulosin)
• 5-Alpha Reductase Inhibitors
• Catheterization
• Surgical Intervention (TURP)

Global Urinary Retention Therapeutics Market Size by Cause & CAGR (2026-2033)

• Market Overview
• Benign Prostatic Hyperplasia (BPH)
• Neurogenic
• Drug-Induced

Global Urinary Retention Therapeutics Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Retail Pharmacies
• Hospital Pharmacies

Global Urinary Retention Therapeutics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Urology Clinics
• Hospitals

Global Urinary Retention Therapeutics Market Size & CAGR (2026-2033)

• North America (Treatment Type, Cause, Distribution, End-User)
  • US
  • Canada
• Europe (Treatment Type, Cause, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Cause, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Cause, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Cause, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Astellas Pharma (Flomax)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (Avodart)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NovaBay Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (UroLift)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NxStage Medical (Fresenius)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coloplast A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CR Bard (Becton Dickinson)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rochester Medical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C.R. Bard Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations